Wolverine Trading
RCKT icon

Wolverine Trading’s Rocket Pharmaceuticals RCKT Stock Holding History

Wolverine Trading’s Portfolio RCKT Stock Details RCKT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-15,431
Closed -$48.6K – 6068
2025
Q2 		$39K Buy
+15,431
New +$78.2K ﹤0.01% 4397
2025
Q1 		– Sell
-17,588
Closed -$174K – 5629
2024
Q4 		$212K Buy
+17,588
New +$265K ﹤0.01% 4450

Other funds holding RCKT

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
MAM
Monaco Asset Management Monaco $542M AUM 54.4% 1-Year Est. Return
NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return

Wolverine Trading's RCKT Position: Q3 2025 in Review

Wolverine Trading sold out of Rocket Pharmaceuticals (RCKT) in Q3 2025, closing a stake of 15,431 shares — an estimated $48.6K sold.

Wolverine Trading first reported a position in RCKT in Q4 2024 and held it in 2 quarters. The position peaked at $212K in Q4 2024. 173 funds tracked by Wall St. Rank hold RCKT as of Q3 2025.

  • Wolverine Trading reported no remaining Rocket Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • Wolverine Trading sold 15,431 Rocket Pharmaceuticals shares in Q3 2025, an estimated $48.6K.
  • Wolverine Trading first reported a position in Rocket Pharmaceuticals in Q4 2024 and held it in 2 quarters.
  • Wolverine Trading's Rocket Pharmaceuticals position peaked at $212K in Q4 2024.
  • 173 funds tracked by Wall St. Rank held Rocket Pharmaceuticals as of Q3 2025.

Based on Wolverine Trading's 13F filing for Q3 2025, filed 14 Nov 2025.